Advanced search×

Access to safety data--stockholders versus prescribers.

Marc A MA Pfeffer and Marianne B MB Bowler

N Engl J Med 365(1):1-3 (2011) PMID 21714642

DOI: 10.1056/NEJMp1104699
Version: za2963e q8za0 q8zbe q8zcf q8zd4 q8zee q8zff q8zg6
View PDF

Similar articles you may find interesting…

  1. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for r...
    Mark Cascione, Daniel Wynn, and Kevin McCague

    J Med Econ (2013) PMID 23647445

    Results of the EPOC study are anticipated in early 2013 and will inform treatment selection by providing patient-centered data on therapy switch to fingolimod or standard-of-care DMTs. Trial Registration: ClinicalTrials.gov NCT01216072....
    Buy PDF
  2. A review of age related dehydroepiandrosterone (DHEA) decline and its association with well-known geriatric syndromes. Is treatment benefici...
    Nikolaos Samaras, Dimitrios Samaras, and Jacques Philippe

    Rejuvenation Res (2013) PMID 23647054

    We examine the potential relation between low dehydroepiandrosterone levels and well-known age-related diseases such as sarcopenia, osteoporosis, dementia, sexual disorders and cardiovascular disease. We also review risks and benefits of existing protocols of dehydroepiandrosterone supplementation....
    Buy PDF
  3. Enzymatic Detoxification, Conformational Selection, and the Role of Molten Globule Active Sites.
    Matthew T Honaker, Mauro Acchione, and William M Atkins

    J Biol Chem (2013) PMID 23649628

    We propose that local molten globule behavior optimizes detoxification enzymes....
    PDF not found